Alembic Pharma USFDA approvals: 27m-73m US markets

Why Alembic’s latest USFDA clearances matter

Alembic Pharmaceuticals Limited has disclosed a series of US Food and Drug Administration (USFDA) final approvals for its Abbreviated New Drug Applications (ANDAs), adding more products that can be marketed in the United States. The approvals span both oral solid dosage forms and injectables, highlighting the company’s breadth across therapies and delivery formats. In multiple filings and announcements, Alembic has repeatedly stated that its approved ANDAs are therapeutically equivalent to the respective reference listed drug products (RLDs).

For an India-listed pharma company, US approvals are closely tracked because they can expand the addressable market and add to the portfolio of launches in international generics. The updates also provide a snapshot of Alembic’s ANDA approval count across different time periods, reflecting the pace of filings and regulatory outcomes.

Methotrexate Injection approval referenced in the announcement

The corporate announcement text references USFDA final approval for Methotrexate Injection USP in two presentations: 50 mg/2 mL and 1 g/40 mL. It describes this as an addition that expands Alembic’s ANDA portfolio with a therapeutically equivalent injectable treatment. Beyond the dosage strengths and the “final approval” status, no further product-specific commercial details are provided in the supplied text.

Lamotrigine orally disintegrating tablets: strengths and reference drug

Alembic also announced USFDA final approval for its ANDA for Lamotrigine Orally Disintegrating Tablets (ODT) USP in four strengths: 25 mg, 50 mg, 100 mg, and 200 mg. The company stated that the approved ANDA is therapeutically equivalent to the RLD, Lamictal ODT Orally Disintegrating Tablets, in the same strengths, of GlaxoSmithKline LLC.

The announcement specifies the drug’s clinical use. Lamotrigine is indicated as adjunctive therapy in patients aged 2 years and older for partial-onset seizures, primary generalized tonic-clonic (PGTC) seizures, and generalized seizures of Lennox-Gastaut syndrome. It is also indicated for conversion to monotherapy in adults aged 16 years and older with partial-onset seizures who are receiving certain other antiepileptic drugs as the single AED.

Market size data shared for Lamotrigine ODT

The provided text (including a Hindi-language summary) states that the market size for Lamotrigine ODT is USD 27 million, based on the last 12 months’ data up to December. The same summary adds that, following this approval, Alembic’s total USFDA ANDA approvals reached 235, comprising 216 final approvals and 19 tentative approvals.

Separately, the text notes that the approval enables Alembic to sell and market Lamotrigine ODT in the US, and frames this as supportive of the company’s position in the US generics market. These statements are consistent with the functional implication of a final ANDA approval, without detailing specific launch timing.

Sumatriptan Injection: autoinjector system and IQVIA market estimate

Another announcement in the supplied content states that Alembic received USFDA final approval for its ANDA for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, in a Single-Dose Autoinjector System. Alembic said the approved ANDA is therapeutically equivalent to the RLD, Imitrex STATdose System, 4 mg/0.5 mL and 6 mg/0.5 mL, of GlaxoSmithKline Intellectual Property Ltd, England.

According to IQVIA data cited in the text, the therapy has an estimated US market size of USD 73 million as of September (year not specified in the provided excerpt). The announcement also states that Sumatriptan injection is indicated for the treatment of migraine and cluster headache.

Other USFDA approvals cited: Triamcinolone and Macitentan

The content also references Alembic’s USFDA final approval for Triamcinolone Acetonide Injectable Suspension USP. The strengths listed include 40 mg/mL single-dose vials and multiple-dose vials of 200 mg/5 mL and 400 mg/10 mL (40 mg/mL). Alembic said the approved ANDA is therapeutically equivalent to Kenalog-40 Injectable Suspension, the RLD of Bristol-Myers Squibb Company.

In addition, the text mentions USFDA final approval for Macitentan Tablets, 10 mg. Alembic stated that the approved ANDA is therapeutically equivalent to Opsumit Tablets, 10 mg, of Actelion Pharmaceuticals US, Inc.

Carbamazepine extended-release: stock move and market size estimate

Another disclosure in the supplied text states Alembic received USFDA final approval for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. The company stated the approved ANDA is therapeutically equivalent to Tegretol-XR Extended-Release Tablets in the same strengths, the RLD of Novartis Pharmaceuticals Corporation.

The report also captures an immediate market reaction. Alembic Pharmaceuticals shares rose in early trade on July 28, and at 09:21 am the stock was quoted at Rs 1,010.50, up Rs 12.20 or 1.22% on the BSE. The Hindi summary further cites IQVIA data that the estimated market size for Carbamazepine extended-release tablets in the US was USD 71 million for the 12 months ended March 2025.

ANDA approval counts: what the disclosures show

The supplied content includes multiple ANDA approval totals attributed to Alembic across different announcements. One disclosure states a cumulative total of 227 ANDA approvals from USFDA, consisting of 206 final approvals and 21 tentative approvals. Another states a cumulative total of 225 ANDA approvals, consisting of 202 final approvals and 23 tentative approvals. The later Hindi summary tied to Lamotrigine ODT cites 235 total approvals, consisting of 216 final approvals and 19 tentative approvals.

Because these totals appear in different contexts, they should be read as point-in-time snapshots from separate announcements, rather than as a single consolidated figure for one date.

Key facts at a glance

What “therapeutically equivalent” signals in these approvals

Across the announcements, Alembic repeatedly states that its approved ANDAs are therapeutically equivalent to the corresponding RLDs. In practical terms, the language is used to indicate equivalence to the branded reference product named in the approval disclosure. This framing is important in US generics because it clarifies what the generic product is referenced against in the regulatory filing.

The disclosures also show Alembic’s continued focus on a mix of CNS therapies (such as lamotrigine and carbamazepine) and injectables, including device-linked presentations like an autoinjector system for sumatriptan. That combination is visible directly from the product list and dosage forms stated in the announcements.

Conclusion

Alembic’s set of USFDA final approvals across Lamotrigine ODT, Sumatriptan Injection, Carbamazepine extended-release tablets, and other products cited in the supplied text adds to the company’s US portfolio across multiple therapies and formats. The announcements also provide market size estimates for select products of USD 27 million, USD 73 million, and USD 71 million, and include a reported early-trade stock move following the Carbamazepine approval disclosure. Future updates are likely to come through subsequent exchange filings and product-specific launch communications, as seen in the pattern of the announcements included here.